Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the B. Riley Securities 3 rd Annual Virtual Oncology Conference on January 18 at 1 p.m. ET.
A live webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events . Following the presentation, the webcast will be archived and available for replay for a period of 30 days.
About Geron
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005297/en/
Aron Feingold
Investor and Media Relations
investor@geron.com
media@geron.com